Ozobax is owned by Metacel Pharms Llc.
Ozobax contains Baclofen.
Ozobax has a total of 1 drug patent out of which 0 drug patents have expired.
Ozobax was authorised for market use on 18 September, 2019.
Ozobax is available in solution;oral dosage forms.
Ozobax can be used as treatment of spasticity.
The generics of Ozobax are possible to be released after 30 August, 2039.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610502 | METACEL PHARMS LLC | Oral baclofen solutions |
Aug, 2039
(16 years from now) |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 18 September, 2019
Treatment: Treatment of spasticity
Dosage: SOLUTION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic